This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
UBS Remains a Buy on Alcon (ALC)
In a report released today, Graham Doyle from UBS maintained a Buy rating on Alcon, with a price target of CHF95.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Doyle is an analyst with an average return of -1.4% and a 51.88% success rate. Doyle covers the Healthcare sector, focusing on stocks such as Fresenius Medical Care AG & Co. KGaA, Fresenius SE & Co. KGaA, and Koninklijke Philips N.V..
In addition to UBS, Alcon also received a Buy from BTIG’s Ryan Zimmerman in a report issued on March 9. However, on the same day, Stifel Nicolaus maintained a Hold rating on Alcon (NYSE: ALC).
The company has a one-year high of CHF85.16 and a one-year low of CHF57.68. Currently, Alcon has an average volume of 1.08M.
Read More on ALC:
Disclaimer & DisclosureReport an Issue
- Alcon price target raised to $82 from $80 at Stifel
- Goldman Sachs Sees Market Warning Signs – But Likes These 2 Stocks
- Alcon Earnings Call: Growth, Tariffs and Margin Plans
- Spotify upgraded, First Solar downgraded: Wall Street’s top analyst calls
- Wells Fargo upgrades Alcon to Overweight on new product growth
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
